Certainly. Currently the amount of funding we've been able to attract as a result of our financial outlay—currently of approximately $30 million—is close to $96 million. The exact figure is $95.78 million. This is as a result of being able to connect all of the dots that are necessary in order to advance a preclinical asset all the way through to a clinical trial.
When you build these types of engines that work, that are producing results, that are filled with experts and the right clinicians who are developing some very exciting assets, the private sector takes notice and wishes to invest.
Another key point to recall is that when we work at BioCanRx, we utilize a pipeline approach, and because we're a mission-oriented organization we are very much looking to increase the number of clinical trials, so that a greater number of patients in Canada can benefit from domestic clinical trials. We invest in the technology keeping in mind what the clinical trial for this is going to look like, and as we progress down that pipeline, the amount of monies that we're able to attract from the private sector, of course, increases.
Therefore, in terms of leverage ratios in our clinical trial program, we're approaching ratios of 8:1 on the dollar, and that's because greater value has been introduced into the assets under development.